



AVALON
GLOBOCARE CORP.

Corporate Presentation

March 2023

www.avalon-globocare.com

Nasdaq: ALBT

Forward-Looking Statements

Certain statements contained in this presentation may constitute “forward-looking statements”, which provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (<http://www.sec.gov>). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this presentation represent the Company's views as of the date of this presentation and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this presentation.

Corporate Overview and Highlights

Mission: Avalon GloboCare Corp. (Nasdaq: ALBT) is a clinical-stage biotechnology company and laboratory testing provider dedicated to developing and delivering innovative, transformative CellTech (cell-based technologies and therapeutics), precision diagnostics, and clinical laboratory services

History: Founded in 2016; successfully uplisted to Nasdaq in December 2018; Acquired Laboratory Services LLC in February 2023; Headquarters in Freehold, New Jersey; approx. 60 FTEs (including subsidiaries)

Core Technology Platforms:

- **Cellular Immunotherapies**
Including Chimeric Antigen Receptor (CAR)-T, mRNA-based FLASH CAR™ and AVA-Trap™
- **Precision Diagnostics / Clinical Laboratory Services**



Avalon's Dual Driving Engines

CellTech



**Precision
Dx**

***Accelerate the development of better and safer
cellular medicines***

Laboratory Services MSO Acquisition



- Accelerate precision diagnostics related to better, safer future development of cellular therapies
- Access to the world's largest clinical outcome database related to BMT and cellular immunotherapies
- Large-scale lab testing related to immune system functionality, toxicity monitoring and immune wellness maintenance
- **Accretive to earnings: achieved unaudited revenue in excess of \$18 million income and \$8.5 M of EBITDA 2022**

